- Home
- IVZ vs BBIO Comparison
IVZ vs BBIO Comparison
Compare IVZ & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVZ
- BBIO
- Stock Information
- Founded
- IVZ 1935
- BBIO 2015
- Country
- IVZ United States
- BBIO United States
- Employees
- IVZ N/A
- BBIO N/A
- Industry
- IVZ Investment Managers
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- IVZ Finance
- BBIO Health Care
- Exchange
- IVZ Nasdaq
- BBIO Nasdaq
- Market Cap
- IVZ 9.9B
- BBIO 10.4B
- IPO Year
- IVZ 1995
- BBIO 2019
- Fundamental
- Price
- IVZ $24.06
- BBIO $66.46
- Analyst Decision
- IVZ Hold
- BBIO Strong Buy
- Analyst Count
- IVZ 16
- BBIO 16
- Target Price
- IVZ $22.34
- BBIO $66.50
- AVG Volume (30 Days)
- IVZ 6.2M
- BBIO 2.5M
- Earning Date
- IVZ 10-28-2025
- BBIO 10-29-2025
- Dividend Yield
- IVZ 3.48%
- BBIO N/A
- EPS Growth
- IVZ N/A
- BBIO N/A
- EPS
- IVZ 1.47
- BBIO N/A
- Revenue
- IVZ $6,278,100,000.00
- BBIO $353,780,000.00
- Revenue This Year
- IVZ N/A
- BBIO $115.12
- Revenue Next Year
- IVZ $10.02
- BBIO $65.29
- P/E Ratio
- IVZ $16.37
- BBIO N/A
- Revenue Growth
- IVZ 6.64
- BBIO 62.46
- 52 Week Low
- IVZ $11.60
- BBIO $21.72
- 52 Week High
- IVZ $24.75
- BBIO $69.48
- Technical
- Relative Strength Index (RSI)
- IVZ 63.94
- BBIO 76.88
- Support Level
- IVZ $20.67
- BBIO $52.75
- Resistance Level
- IVZ $24.75
- BBIO $69.48
- Average True Range (ATR)
- IVZ 0.84
- BBIO 2.56
- MACD
- IVZ 0.04
- BBIO 1.16
- Stochastic Oscillator
- IVZ 82.97
- BBIO 81.95
About IVZ Invesco Ltd
Invesco provides investment-management services to retail (68% of managed assets) and institutional (32%) clients. At the end of July 2025, the firm had $2.025 trillion in assets under management spread among its equity (60% of AUM), balanced (3%), fixed-income (21%), alternative investment (6%), and money market (10%) operations. Passive products account for 46% of Invesco's total AUM. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 30% of its AUM sourced from Europe, Africa, and the Middle East (15%) and Asia (15%).
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.